KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Novavax's Current Deferred Revenue fell 55.58% to $501.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.4 million, marking a year-over-year decrease of 55.58%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.92% up from last year.
  • As of FY2024, Novavax's Current Deferred Revenue stood at $1.1 billion, which was up 29.92% from $863.5 million recorded in FY2023.
  • In the past 5 years, Novavax's Current Deferred Revenue ranged from a high of $1.6 billion in FY2021 and a low of $300.0 million during FY2020.
  • In the last 3 years, Novavax's Current Deferred Revenue had a median value of $863.5 million in 2023 and averaged $845.0 million.
  • In the last 5 years, Novavax's Current Deferred Revenue soared by 17,547.06% in 2020 and then plummeted by 65.56% in 2022.
  • Yearly analysis of 5 years shows Novavax's Current Deferred Revenue stood at $300.0 million in 2020, then surged by 431.82% to $1.6 billion in 2021, then slumped by 65.56% to $549.6 million in 2022, then soared by 57.13% to $863.5 million in 2023, then increased by 29.92% to $1.1 billion in 2024.